Clinical phase III comparative study of intravenous levofloxacin and ceftriaxone in community-acquired pneumonia treatment

Japanese Journal of Chemotherapy

Volumn 59, Issue SUPPL. 1, 2011, Pages 32-45

  Kohno, Shigeru ^a   Watanabe, Akira ^b   Aoki, Nobuki ^c   Niki, Yoshihito ^d   Kadota, Junichi ^e   Fujita, Jiro ^f   Yanagihara, Katsunori ^a   Kaku, Mitsuo ^g   Hori, Seiji ^h  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Shinrakuen Hospital   (Japan)

^d SHOWA UNIVERSITY   (Japan)

^e OITA UNIVERSITY   (Japan)

^f UNIVERSITY OF THE RYUKYUS   (Japan)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Community acquired pneumonia; Levofloxacin injection; Randomized controlled trial

Indexed keywords

CEFTRIAXONE; LEVOFLOXACIN;

ARTICLE; BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; HUMAN; MAJOR CLINICAL STUDY; MICROBIOLOGICAL PARAMETERS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79959458615     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jpn J Antibiot 2006; 59: 428-51
2. Critchley I A, Jones M E, Heinze P D, Hubbard D, Engler H D, Evangelista A T, et al: In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002; 8: 214-21
3. File T M Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams R R, et al: A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-72 (Pubitemid 27383238)
4. San Pedro G S, Cammarata S K, Oliphant T H, Todisco T; Linezolid Community-Acquired Pneumonia Study Group: Linezolid versus ceftriaxone/ cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002; 34: 720-8 (Pubitemid 35386034)
5. Ortiz-Ruiz G, Vetter N, Isaacs R, Carides A, Woods G L, Friedland I: Ertapenem versus ceftriaxone for the treatment of community-acquired pneumomia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother 2004; 53 (Suppl 2): ii59-66
6. File T M Jr, Low D E, Eckburg P B, Talbot G H, Friedland H D, Lee J, et al: Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51: 1395-405
7. Chemotherapy 1991; 39: 687-9
8. Thorsteinsson S B, Bergan T, Johannesson G, Thorsteinsson H S, Rohwedder R: Tolerance of ciprofloxacin at injection site, systemic safety and effect on electroencephalogram. Chemotherapy 1987; 33: 448-51